All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Drug Solutions Podcast: Cell Therapy Development: Advances, Trends, and the Challenge of Retention

September 20, 2022
By Meg Rivers
News
Podcast

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.

Cell therapies are a hot topic in the bio/pharma industry today. In this episode of the Drug Solutions Podcast, Meg Rivers, senior editor, Andrew Scharenberg, CEO, Umoja Biopharma, and Ryan Crisman, co-founder and chief technical officer, Umoja Biopharma, discuss:

  • The greatest advancements in cell therapy to date
  • Where there’s room for improvement
  • The biggest trends in cell therapy development
  • The pros and cons of developing cell and gene therapies
  • And much more.

In the discussion, one thing that came up a few times was that one of the major challenges in developing cell therapy is retention. This issue, according to the speakers, has led to the current trend for some biopharma companies to insource development rather than outsource to contract development and manufacturing organizations (CDMOs). The speakers also discussed scale up vs. scale out and various challenges and opportunities for autologous and allogeneic therapies.


Sponsors


About the speakers

Dr. Andrew Scharenberg is the CEO of Umoja Biopharma, an MPM portfolio company. He also serves as an executive partner at MPM Capital and chairs the scientific advisory boards at Generation Bio, Genti Bio, and Alpine Immune Sciences. Prior to founding Umoja, Scharenberg co-directed the program in cell and gene therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, partnered with Casebia Therapeutics, for the purpose of developing gene-edited cell therapeutics for type 1 diabetes and other inflammatory diseases. Previously, he was the chief scientific officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform, and was the co-founder of Pregenen Inc., a gene-editing and cell-signaling technology company that was acquired by bluebird bio in 2014.

Ryan Crisman, PhD, is the co-founder and chief technical officer of Umoja Biopharma. Before starting Umoja in 2019, Crisman served as the executive director for the Gates biomanufacturing facility, where he was responsible for building out and staffing this protein and cell therapy CDMO. He was instrumental in growing the facility’s current good manufacturing practice capabilities and delivering many first-in-human therapeutic products to patients. While at Juno Therapeutics, Crisman led the JCAR017 chemistry, manufacturing, and controls program and was the head of late-stage process development. He has also held scientific leadership positions at Zymogenetics and CMC Biologics.


About the Drug Solutions Podcast

Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.

Recent Videos
Behind the Headlines, Episode 17
Related Content

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Feliza Mirasol
March 25th 2025
Podcast

The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.


Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery
May 13th 2025
Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

Related Content

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Drug Solutions Podcast: Equipment Trends for Addressing Production of New Modalities

Feliza Mirasol
March 25th 2025
Podcast

The growing development of new biotherapeutic modalities will rely heavily on automation and progressive technologies.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.


Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.


Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.


Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery
May 13th 2025
Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.